On power and sample size calculation for QT studies with recording replicates at given time point

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 3, 2008, Pages 483-493

  Chow, Shein Chung ^a   Cheng, Bin ^b   Cosmatos, Dennis ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Howard Hughes Medical Institute   (United States)

^c PFIZER INC   (United States)

Author keywords

Correlation coefficient; Crossover design; Measurement error; Parallel group design; QT Studies

Indexed keywords

AB INITIO CALCULATION; ARTICLE; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; ELECTROCARDIOGRAM; PRIORITY JOURNAL; QT INTERVAL; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART RATE; HUMAN; LONG QT SYNDROME; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL MODEL; STATISTICS;

NEW DRUG;

ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; GUIDELINES AS TOPIC; HEART RATE; HUMANS; LONG QT SYNDROME; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 45849089186     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400801995452     Document Type: Article

References (11)

1. Cheng, B., Shao, J. (2007). Exact tests for negligible interaction in two-way linear models. Statistica Sinica 17:1441-1455.
2. Chow, S. C., Shao, J., Wang, H. (2003). Sample Size Calculation in Clinical Research. New York: Marcel Dekker.
3. CPMP (1997). Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular products. Available at: www.coresearch.biz/regulations/cpmp.pdf.
4. FDA/TPD (2003). Preliminary concept paper: The clinical evaluation of QT/QTc interval prolongation and proarrythmic potential for non-arrythmic drug products. Released on November 15, 2002. Revised on February 6, 2003.
5. ICH (2005). ICH E14 Guidance on the Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-Antiarrythmic Drugs. Geneva, Switzerland: International Conference on Harmonisation, May 2005.
6. Longford, N. T. (1993). Random Coefficient Models. New York: Oxford University Press.
7. Malik, M., Camm, A. J. (2001). Evaluation of drug-induced QT interval prolongation. Drug Safety 24:323-351.
8. Moss, A. J. (1993). Measurement of the QT interval and the risk associated with QT interval prolongation. American Journal of Cardiology 72:23B-25B.
9. PhRMA (2003). Investigating drug-induced QT and QTc prolongation in the clinic: Statistical design and analysis considerations. Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team, August 14, 2003.
10. Strieter, D., Wu, W., Agin, M. (2003). Assessing the effects of replicate ECGs on QT variability in healthy subjects. Presented at Midwest Biopharmaceutical Workshop, May 21, 2003.
11. Temple, R. (2003). Overview of the concept paper, history of the QT/TdP concern; regulatory implications of QT prolongation. Presentations at Drug Information Agency/FDA Workshop. Available at: www.diahome.org.